Bucindolol beta blocker targeted to beta receptors in the heart and vasculature: Subsidiary Intercardia Inc. began a Phase III trial in up to 2,800 patients, wi

Interneuron Pharmaceuticals (IPIC), Lexington, Mass.

Read the full 56 word article

How to gain access

Continue reading with a
two-week free trial.